Jorg Kleeff

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8824115/publications.pdf

Version: 2024-02-01

468 papers	27,837 citations	5574 82 h-index	8630 146 g-index
525 all docs	525 docs citations	525 times ranked	29459 citing authors

#	Article	IF	Citations
1	Early Drain Removal is Safe in Patients With Low or Intermediate Risk of Pancreatic Fistula After Pancreaticoduodenectomy. Annals of Surgery, 2022, 275, e307-e314.	4.2	18
2	Sca-1 is a marker for cell plasticity in murine pancreatic epithelial cells and induced by IFN-Î² inÂvitro. Pancreatology, 2022, , .	1.1	4
3	Cancer-Associated Fibroblasts and Tumor Cells in Pancreatic Cancer Microenvironment and Metastasis: Paracrine Regulators, Reciprocation and Exosomes. Cancers, 2022, 14, 744.	3.7	14
4	Intracystic Papillary Neoplasm of the Gallbladder. Journal of Gastrointestinal Surgery, 2022, 26, 982-984.	1.7	1
5	Acute and chronic mesenteric ischemia: single center analysis of open, endovascular, and hybrid surgery. BMC Surgery, 2022, 22, 56.	1.3	7
6	Lymph Node Yield in Gastrointestinal Cancer Surgery With or Without Prior Neoadjuvant Therapy: Protocol for a Systematic Review and Meta-analysis. JMIR Research Protocols, 2022, 11, e35243.	1.0	1
7	Systematic review and meta-analysis of surgery for hilar cholangiocarcinoma with arterial resection. Hpb, 2022, 24, 1600-1614.	0.3	2
8	Management of an abdominal penetration injury due to a car accident. Trauma Case Reports, 2022, 39, 100646.	0.4	1
9	Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Gut, 2021, 70, gutjnl-2019-319990.	12.1	36
10	Synchronous arterial resections in pancreatic cancer â€“ still a matter of debate?. European Journal of Surgical Oncology, 2021, 47, 480-482.	1.0	6
11	Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival. International Journal of Cancer, 2021, 148, 1919-1927.	5.1	17
12	Types of Pancreatic Resections. Encyclopedia of Pathology, 2021, , 1-6.	0.0	0
13	OUP accepted manuscript. British Journal of Surgery, 2021, , .	0.3	5
14	Do arterial resections improve survival in pancreatic cancer?â€”a narrative review. Chinese Clinical Oncology, 2021, 10, 48-48.	1.2	2
15	Multimodal Therapy of Upper Gastrointestinal Malignancies. Cancers, 2021, 13, 793.	3.7	1
16	A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome Medicine, 2021, 13, 15.	8.2	15
17	Targeting and Reprograming Cancer-Associated Fibroblasts and the Tumor Microenvironment in Pancreatic Cancer. Cancers, 2021, 13, 697.	3.7	25
18	mTORC1 and mTORC2 Converge on the Arp2/3 Complex to Promote KrasG12D-Induced Acinar-to-Ductal Metaplasia and Early Pancreatic Carcinogenesis. Gastroenterology, 2021, 160, 1755-1770.e17.	1.3	24

#	Article	IF	Citations
19	Management problems in patients with pancreatic cancer from a surgeon's perspective. Seminars in Oncology, 2021, 48, 76-83.	2.2	8
20	Current concepts and evidence on open, endovascular and hybrid treatment of mesenteric ischemia: The retrograde open mesenteric stenting. Surgery in Practice and Science, 2021, 5, 100022.	0.4	3
21	The in situ near-total pancreatectomy (LIVOCADO procedure) for end-staged chronic pancreatitis. Langenbeck's Archives of Surgery, 2021, , 1.	1.9	1
22	Identification of prognostic lipid droplet-associated genes in pancreatic cancer patients via bioinformatics analysis. Lipids in Health and Disease, 2021, 20, 58.	3.0	34
23	Surgery With Arterial Resection for Hilar Cholangiocarcinoma: Protocol for a Systematic Review and Meta-analysis. JMIR Research Protocols, 2021, 10, e31212.	1.0	2
24	AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. Gastroenterology, 2021, 161, 1601-1614.e23.	1.3	10
25	Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancerâ€"A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 4326.	3.7	18
26	Lipid Droplet-Associated Factors, PNPLA3, TM6SF2, and HSD17B Proteins in Hepatopancreatobiliary Cancer. Cancers, 2021, 13, 4391.	3.7	13
27	Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. European Journal of Cancer Prevention, 2021, 30, 423-430.	1.3	0
28	Hepatic Activation of FOXO3 Is Associated with Pentose Phosphate Pathway Activation as Well as mTORC2-Akt Signaling and Enhances Oxidative Damage-Associated Hepatocellular Carcinogenesis. Hpb, 2021, 23, S138-S139.	0.3	0
29	Vascular Resections in Surgery for Pancreatic Cancer. Encyclopedia of Pathology, 2021, , 1-5.	0.0	0
30	Anatomic Variants. Encyclopedia of Pathology, 2021, , 1-6.	0.0	0
31	Surgical Oncology: Multidisciplinarity to Improve Cancer Treatment and Outcomes. Current Oncology, 2021, 28, 4471-4473.	2.2	3
32	Interventions to reduce the incidence of surgical site infection in colorectal resections: systematic review with multicomponent network meta-analysis (INTRISSI): study protocol. BMJ Open, 2021, 11, e057226.	1.9	1
33	International consensus guidelines for surgery and the timing of intervention in chronic pancreatitis. Pancreatology, 2020, 20, 149-157.	1.1	68
34	Expression of the EWSR1-FLI1 fusion oncogene in pancreas cells drives pancreatic atrophy and lipomatosis. Pancreatology, 2020, 20, 1673-1681.	1.1	4
35	Surgery for Pancreatic Cancer. , 2020, , 576-586.		0
36	Early drain removal after major pancreatectomy reduces postoperative complications: a single-center, randomized, controlled trial. Journal of Pancreatology, 2020, 3, 93-100.	0.9	13

#	Article	IF	Citations
37	Systematic review and meta-analysis of contemporary pancreas surgery with arterial resection. Langenbeck's Archives of Surgery, 2020, 405, 903-919.	1.9	23
38	Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. JAMA Oncology, 2020, 6, 1733.	7.1	85
39	Cellular Heterogeneity of Pancreatic Stellate Cells, Mesenchymal Stem Cells, and Cancer-Associated Fibroblasts in Pancreatic Cancer. Cancers, 2020, 12, 3770.	3.7	31
40	Hepatic activation of FOXO3 triggers positive feedback-loop for mTORC2-Akt and enhances oxidative damage-associated hepatocellular carcinogenesis. Journal of Hepatology, 2020, 73, S652.	3.7	0
41	International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. Pancreatology, 2020, 20, 910-918.	1.1	39
42	Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review. Scientific Reports, 2020, 10, 4444.	3.3	34
43	Surgery in practice and science. Surgery in Practice and Science, 2020, 1, 100003.	0.4	0
44	Precision oncology for pancreatic cancer in real-world settings. Lancet Oncology, The, 2020, 21, 469-471.	10.7	2
45	Management of the pancreatic transection plane after left (distal) pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). Surgery, 2020, 168, 72-84.	1.9	48
46	Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Doseâ€“Response Relationships. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1009-1018.	2.5	39
47	Combined blockade of TGf-Î²1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Cancer Immunology, Immunotherapy, 2020, 69, 1477-1492.	4.2	38
48	The role of total pancreatectomy with islet autotransplantation in the treatment of chronic pancreatitis: A report from the International Consensus Guidelines in chronic pancreatitis. Pancreatology, 2020, 20, 762-771.	1.1	41
49	Clinical Outcomes after Total Pancreatectomy. Annals of Surgery, 2020, Publish Ahead of Print, .	4.2	13
50	Acute Necrotizing Pancreatitis Post-Pancreatoduodenectomy. , 2020, , 259-262.		0
51	Loss of TLR3 and its downstream signaling accelerates acinar cell damage in the acute phase of pancreatitis. Pancreatology, 2019, 19, 149-157.	1.1	6
52	Oncogenic Akt-FOXO3 loop favors tumor-promoting modes and enhances oxidative damage-associated hepatocellular carcinogenesis. BMC Cancer, 2019, 19, 887.	2.6	22
53	Ring1b-dependent epigenetic remodelling is an essential prerequisite for pancreatic carcinogenesis. Gut, 2019, 68, 2007-2018.	12.1	27
54	Immunotherapy of pancreatic cancer. Progress in Molecular Biology and Translational Science, 2019, 164, 189-216.	1.7	41

#	Article	IF	Citations
55	Differentiation of Autoimmune Pancreatitis from Pancreatic Cancer Remains Challenging. World Journal of Surgery, 2019, 43, 1604-1611.	1.6	26
56	Analyzing the impact of epigenetic profiles on the reprogramming efficiency in different pancreatic cancer subtypes. Pancreatology, 2019, 19, S82.	1.1	0
57	Do we need sequential local therapy following neoadjuvant chemotherapy for locally advanced pancreatic cancer?. EClinicalMedicine, 2019, 17, 100222.	7.1	7
58	Post cholecystectomy bile duct injury: early, intermediate or late repair with hepaticojejunostomy â€“ an E-AHPBA multi-center study. Hpb, 2019, 21, 1641-1647.	0.3	35
59	Response to Comment on â€œThe Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinomaâ€•by Niccolo Petrucciani, MD, PhD, FACS, Laura Antolino, MD, Giovanni Moschetta, MD, Giovanni Ramacciato, MD, FACS. Annals of Surgery, 2019, 270, e130-e131.	4.2	1
60	Pancreatic cancer surgery with vascular resection: current concepts and perspectives. Journal of Pancreatology, 2019, 2, 1-5.	0.9	17
61	Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological caseâ€“control approaches. International Journal of Cancer, 2019, 144, 1540-1549.	5.1	11
62	Interâ€•and intraâ€tumoural heterogeneity in cancerâ€associated fibroblasts of human pancreatic ductal adenocarcinoma. Journal of Pathology, 2019, 248, 51-65.	4.5	215
63	Ductal obstruction promotes formation of preneoplastic lesions from the pancreatic ductal compartment. International Journal of Cancer, 2019, 144, 2529-2538.	5.1	5
64	Outcomes and Risk Score for Distal Pancreatectomy with Celiac Axis Resection (DP-CAR): An International Multicenter Analysis. Annals of Surgical Oncology, 2019, 26, 772-781.	1.5	73
65	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2019, 269, 520-529.	4.2	189
66	Severe Colitis After an Alcohol Enema. American Journal of Gastroenterology, 2018, 113, 172.	0.4	0
67	Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. International Journal of Epidemiology, 2018, 47, 473-483.	1.9	29
68	Therapeutic developments in pancreatic cancer: current and future perspectives. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 333-348.	17.8	762
69	Arterial Resection in Pancreatic Cancer. , 2018, , 1089-1104.		0
70	Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Annals of Surgical Oncology, 2018, 25, 1440-1447.	1.5	73
71	Dynamic landscape of pancreatic carcinogenesis reveals early molecular networks of malignancy. Gut, 2018, 67, 146-156.	12.1	43
72	Pancreatic Cancer and FOLFIRINOX. Annals of Surgery, 2018, 267, e35-e36.	4.2	3

#	Article	IF	Citations
73	Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2018, 6, 429-449.	4.5	22
74	Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2018, 155, 1625-1639.e2.	1.3	152
75	Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells. Cancers, 2018, 10, 3.	3.7	103
76	Peroxisome Proliferator-Activated Receptor gamma negatively regulates liver regeneration after partial hepatectomy via the HGF/c-Met/ERK1/2 pathways. Scientific Reports, 2018, 8, 11894.	3.3	5
77	Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Gut, 2017, 66, 314-322.	12.1	56
78	Effect of preoperative biliary drainage on bacterial flora in bile of patients with periampullary cancer. British Journal of Surgery, 2017, 104, e182-e188.	0.3	74
79	Targeted therapy of pancreatic cancer: biomarkers are needed. Lancet Oncology, The, 2017, 18, 421-422.	10.7	11
80	Peer review report 1 on â€œSafety and feasibility of single-incision laparoscopic cholecystectomy in obese patientsâ€• Annals of Medicine and Surgery, 2017, 13, 57.	1.1	0
81	A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. Annals of Oncology, 2017, 28, 1618-1624.	1.2	20
82	Chronic pancreatitis. Nature Reviews Disease Primers, 2017, 3, 17060.	30.5	339
83	Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes. Scientific Reports, 2017, 7, 41064.	3.3	88
84	Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 1461-1470.	7.0	60
85	Contemporary strategies to improve the outcome in locally advanced pancreatic cancer. Minerva Surgery, 2017, 72, 424-431.	0.6	0
86	Activated leukocyte cell adhesion molecule regulates the interaction between pancreatic cancer cells and stellate cells. Molecular Medicine Reports, 2016, 14, 3627-3633.	2.4	7
87	Canonical NFâ€ºB signaling in hepatocytes acts as a tumorâ€suppressor in hepatitis B virus surface antigenâ€driven hepatocellular carcinoma by controlling the unfolded protein response. Hepatology, 2016, 63, 1592-1607.	7.3	51
88	Arterial Resection in Pancreatic Cancer. , 2016, , 1-16.		1
89	In vivo functional dissection of a context-dependent role for Hif1Î± in pancreatic tumorigenesis. Oncogenesis, 2016, 5, e278-e278.	4.9	7
90	Peer review report 2 on â€œTreatment of choledochal cyst in a pediatric population. A single institution experience of 15-years. Case seriesâ€• Annals of Medicine and Surgery, 2016, 5, S55.	1.1	0

#	Article	IF	Citations
91	Pancreatogastrostomy Versus Pancreatojejunostomy for RECOnstruction After PANCreatoduodenectomy (RECOPANC, DRKS 00000767). Annals of Surgery, 2016, 263, 440-449.	4.2	257
92	Obstructive pancreatitis is a stronger fibrogenic stimulus than cancer-specific stellate cell activation in pancreatic ductal adenocarcinoma. Pancreatology, 2016, 16, S36-S37.	1.1	1
93	The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. British Journal of Cancer, 2016, 115, 887-894.	6.4	48
94	Pancreatic cancer. Nature Reviews Disease Primers, 2016, 2, 16022.	30.5	1,301
95	Periostin and tumor-stroma interactions in non-small cell lung cancer. Oncology Letters, 2016, 12, 3804-3810.	1.8	18
96	Value of diffusion-weighted MR imaging in the diagnosis of lymph node metastases in patients with cholangiocarcinoma. Abdominal Radiology, 2016, 41, 1937-1941.	2.1	24
97	Peer review report 3 on â€œEvaluation of the minimally invasive parathyroidectomy in patients with primary hyperparathyroidism: A retrospective cohort studyâ€• Annals of Medicine and Surgery, 2016, 5, S113.	1.1	0
98	A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. Gut, 2016, 65, 647-657.	12.1	57
99	Outcome of gastric cancer in the elderly: a population-based evaluation of the Munich Cancer Registry. Gastric Cancer, 2016, 19, 713-722.	5.3	36
100	Pathobiology of pancreatic cancer: implications on therapy. Expert Review of Anticancer Therapy, 2016, 16, 219-227.	2.4	3
101	Loss of Periostin Results in Impaired Regeneration and Pancreatic Atrophy after Cerulein-Induced Pancreatitis. American Journal of Pathology, 2016, 186, 24-31.	3.8	25
102	Assessment of Response to Preoperative Therapy. , 2016, , 143-157.		0
103	The role of hypoxia in pancreatic cancer: a potential therapeutic target?. Expert Review of Gastroenterology and Hepatology, 2016, 10, 301-316.	3.0	114
104	Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. Gastroenterology, 2016, 150, 513-525.e10.	1.3	78
105	Polycomb repressor complex 1 promotes gene silencing through H2AK119 mono-ubiquitination in acinar-to-ductal metaplasia and pancreatic cancer cells. Oncotarget, 2016, 7, 11424-11433.	1.8	29
106	Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy?. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 211-213.	0.2	3
107	Evidence-Based Surgical Treatments for Chronic Pancreatitis. Deutsches Ärzteblatt International, 2016, 113, 489-96.	0.9	27
108	Abstract B01: Epigenetic alterations mediated by Ring1b are crucial for acinar-to-ductal metaplasia and pancreatic carcinogenesis. , 2016, , .		0

#	Article	IF	Citations
109	Epigenetic changes mediated by the polycomb repressor complex 1 in acinar-to-ductal metaplasia and pancreatic carcinogenesis. Pancreatology, 2015, 15, S44.	1.1	0
110	Periostin promotes pancreatic carcinogenesis and metastatic spread. Pancreatology, 2015, 15, S33.	1.1	0
111	A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels. Scientific Reports, 2015, 5, 8109.	3.3	18
112	P0284 : Type 2 diabetes promotes hepatocarcinogenesis by inhibiting the induction of senescence after DNA damage. Journal of Hepatology, 2015, 62, S414.	3.7	0
113	Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma. Molecular Cancer, 2015, 14, 212.	19.2	11
114	Postoperative negative-pressure incision therapy following open colorectal surgery (Poniy): study protocol for a randomized controlled trial. Trials, 2015, 16, 471.	1.6	17
115	Loss of Ifnar1 in Pancreatic Acinar Cells Ameliorates the Disease Course of Acute Pancreatitis. PLoS ONE, 2015, 10, e0143735.	2.5	4
116	Wound Edge Protectors in Open Abdominal Surgery to Reduce Surgical Site Infections: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0121187.	2.5	48
117	Surgery for Cystic Pancreatic Lesions in the Post-Sendai Era: A Single Institution Experience. HPB Surgery, 2015, 2015, 1-5.	2.2	16
118	Intra-operative wound irrigation to reduce surgical site infections after abdominal surgery: a systematic review and meta-analysis. Langenbeck's Archives of Surgery, 2015, 400, 167-181.	1.9	109
119	Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Clinical Cancer Research, 2015, 21, 2325-2337.	7.0	170
120	Preoperative Serum Bilirubin and Lactate Levels Predict Postoperative Morbidity and Mortality in Liver Surgery: A Single-Center Evaluation. Scandinavian Journal of Surgery, 2015, 104, 176-184.	2.6	10
121	Brain Metastasis in Colorectal Cancer Patients: Survival and Analysis of Prognostic Factors. Clinical Colorectal Cancer, 2015, 14, 281-290.	2.3	49
122	Increased expression of Nodal correlates with reduced patient survival in pancreatic cancer. Pancreatology, 2015, 15, 156-161.	1.1	19
123	Outcome after surgery for acute right-sided colonic ischemia without feasible vascular intervention: a single center experience of 58 patients over 6 years. BMC Surgery, 2015, 15, 31.	1.3	12
124	Metabolism gene signatures and surgical site infections in abdominal surgery. International Journal of Surgery, 2015, 14, 67-74.	2.7	3
125	Kif20a inhibition reduces migration and invasion of pancreatic cancer cells. Journal of Surgical Research, 2015, 197, 91-100.	1.6	56
126	Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. Molecular Cancer, 2015, 14, 94.	19.2	210

#	Article	IF	Citations
127	Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut, 2015, 64, 1921-1935.	12.1	112
128	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine, 2015, 21, 1163-1171.	30.7	349
129	Volumetric gain of the human pancreas after left partial pancreatic resection: A CT-scan based retrospective study. Pancreatology, 2015, 15, 542-547.	1.1	15
130	Potential role of Th17 cells in the pathogenesis of type 2 autoimmune pancreatitis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 641-648.	2.8	15
131	Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. Annals of Surgical Oncology, 2015, 22, 1212-1220.	1.5	77
132	Outcomes of resections for pancreatic adenocarcinoma with suspected venous involvement: a single center experience. BMC Surgery, 2015, 15, 100.	1.3	9
133	Umbilical Microflora, Antiseptic Skin Preparation, and Surgical Site Infection in Abdominal Surgery. Surgical Infections, 2015, 16, 450-454.	1.4	19
134	Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. Pancreatology, 2015, 15, 8-18.	1.1	404
135	Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Cancer Letters, 2015, 356, 721-732.	7.2	72
136	Hypoxia-induced endoplasmic reticulum stress characterizes a necrotic phenotype of pancreatic cancer. Oncotarget, 2015, 6, 32154-32160.	1.8	32
137	Abstract B08: The role of periostin in pancreatic carcinogenesis and metastatic spread. , 2015, , .		0
138	RE: Proteomic Mucin Profiling for the Identification of Cystic Precursors of Pancreatic Cancer. Journal of the National Cancer Institute, 2014, 106, dju263-dju263.	6.3	1
139	The evidence based dilemma of intraperitoneal drainage for pancreatic resection â€“ a systematic review and meta-analysis. BMC Surgery, 2014, 14, 76.	1.3	26
140	Multicenter Double-Blinded Randomized Controlled Trial of Standard Abdominal Wound Edge Protection With Surgical Dressings Versus Coverage With a Sterile Circular Polyethylene Drape for Prevention of Surgical Site Infections. Annals of Surgery, 2014, 260, 730-739.	4.2	76
141	Epigenetic changes mediated by the polycomb repressor complex 1 in acinar-to-ductal metaplasia and pancreatic carcinogenesis.. Pancreatology, 2014, 14, S64.	1.1	0
142	675: Therapeutic and diagnostic targeting of gastrointestinal tumors with Shiga Toxin B subunit. European Journal of Cancer, 2014, 50, S163.	2.8	0
143	Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines. Biomedicine and Pharmacotherapy, 2014, 68, 737-743.	5.6	46
144	Multimodal Molecular Imaging of Integrin Î±_vÎ²₃ for In Vivo Detection of Pancreatic Cancer. Journal of Nuclear Medicine, 2014, 55, 446-451.	5.0	43

#	Article	IF	Citations
145	Intracellular autofluorescence: a biomarker for epithelial cancer stem cells. Nature Methods, 2014, 11, 1161-1169.	19.0	170
146	Could hyponatremia be a marker of anastomotic leakage after colorectal surgery? A single center analysis of 1,106 patients over 5Âyears. Langenbeck's Archives of Surgery, 2014, 399, 783-788.	1.9	5
147	Level of hospital care and outcome of gastric cancer: a population-based evaluation of the Munich Cancer Registry. Journal of Cancer Research and Clinical Oncology, 2014, 140, 789-800.	2.5	3
148	Solo-surgical laparoscopic cholecystectomy with a joystick-guided camera device: a caseâ€“control study. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 164-170.	2.4	58
149	Chloroquine Targets Pancreatic Cancer Stem Cells via Inhibition of CXCR4 and Hedgehog Signaling. Molecular Cancer Therapeutics, 2014, 13, 1758-1771.	4.1	135
150	O170 DYSREGULATED UNFOLDED PROTEIN RESPONSE CONTROL IN THE ABSENCE OF CANONICAL IKK/NF-ÎºB SIGNALLING LEADS TO SEVERE LIVER DAMAGE AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2014, 60, S526.	3.7	0
151	Colorectal cancer surgery remains effective with rising patient age. International Journal of Colorectal Disease, 2014, 29, 971-979.	2.2	29
152	Update on surgical treatment of pancreatic neuroendocrine neoplasms. World Journal of Gastroenterology, 2014, 20, 13893.	3.3	23
153	Comparative analysis of the revenues of pylorus-preserving pancreatic head resections and laparoscopic cholecystectomies as prototypic surgical procedures in the German health-care system. Langenbeck's Archives of Surgery, 2013, 398, 825-831.	1.9	0
154	Loss of Ppar-gamma promotes KrasG12D-driven pancreatic ductal adenocarcinoma formation by inhibiting p53 function. Pancreatology, 2013, 13, S57-S58.	1.1	0
155	Pancreaticoduodenectomy in patients with true cancer infiltration of the portal vein is associated with an unfavorable prognosis. Pancreatology, 2013, 13, e4.	1.1	0
156	Analysis of the extracellular matrix protein periostin in early pancreatic carcinogenesis. Pancreatology, 2013, 13, S14-S15.	1.1	0
157	Precancerous lesions of the biliary tree. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 285-297.	2.4	70
158	Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels. Frontiers in Physiology, 2013, 4, 246.	2.8	55
159	First case of spontaneous myospherulosis of the liver. Journal of Clinical Pathology, 2013, 66, 161-163.	2.0	1
160	EU Pancreas: An Integrated European Platform for Pancreas Cancer Research - from Basic Science to Clinical and Public Health Interventions for a Rare Disease. Public Health Genomics, 2013, 16, 305-312.	1.0	2
161	Decrease of Global Methylation Improves Significantly Hepatic Differentiation of Ad-MSCs: Possible Future Application for Urea Detoxification. Cell Transplantation, 2013, 22, 119-131.	2.5	32
162	Minimalinvasive Chirurgie bei Malignomen des Gastrointestinaltrakts: Kolon - Pro-Position. Visceral Medicine, 2013, 29, 382-387.	1.3	1

#	Article	IF	Citations
163	Minimalinvasive Chirurgie bei Malignomen des Gastrointestinaltrakts: Pankreas - Kontra-Position. Visceral Medicine, 2013, 29, 375-381.	1.3	1
164	Loss of acinar cell IKKÎ± triggers spontaneous pancreatitis in mice. Journal of Clinical Investigation, 2013, 123, 2231-2243.	8.2	103
165	Response evaluation following neoadjuvant treatment of pancreatic cancer patients. World Journal of Gastrointestinal Surgery, 2013, 5, 12.	1.5	12
166	Langzeitverlauf der Autoimmunpankreatitis. , 2013, , 176-180.		0
167	Complexity of molecular alterations impacts pancreatic cancer prognosis. World Journal of Gastrointestinal Oncology, 2013, 5, 1.	2.0	1
168	StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut, 2012, 61, 172-178.	12.1	358
169	How fibrosis influences imaging and surgical decisions in pancreatic cancer. Frontiers in Physiology, 2012, 3, 389.	2.8	46
170	The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance. Current Molecular Medicine, 2012, 12, 288-303.	1.3	71
171	Transarterial Chemoembolization of Liver Metastases As Symptomatic Therapy of Lipase Hypersecretion Syndrome. Journal of Clinical Oncology, 2012, 30, e209-e212.	1.6	9
172	HAnd Suture Versus STApling for Closure of Loop Ileostomy (HASTA Trial). Annals of Surgery, 2012, 256, 828-836.	4.2	65
173	Few genes are associated with the capability of pancreatic ductal adenocarcinoma cells to grow in the liver of nude rats. Oncology Reports, 2012, 28, 2177-2187.	2.6	18
174	Human Hepatocytes: Isolation, Culture, and Quality Procedures. Methods in Molecular Biology, 2012, 806, 99-120.	0.9	46
175	The actin binding protein destrin is associated with growth and perineural invasion of pancreatic cancer. Pancreatology, 2012, 12, 350-357.	1.1	14
176	Manufacturing of patient-specific pancreas models for surgical resections. , 2012, , .		5
177	Palliative resections versus palliative bypass procedures in pancreatic cancerâ€"a systematic review. American Journal of Surgery, 2012, 203, 496-502.	1.8	51
178	Syndecan-2 promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype. Molecular Cancer, 2012, 11, 19.	19.2	42
179	Standard abdominal wound edge protection with surgical dressings vs coverage with a sterile circular polyethylene drape for prevention of surgical site infections (BaFO): study protocol for a randomized controlled trial. Trials, 2012, 13, 57.	1.6	11
180	The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 454-467.	17.8	535

#	Article	IF	Citations
181	MALDI Imaging Mass Spectrometry for In Situ Proteomic Analysis of Preneoplastic Lesions in Pancreatic Cancer. PLoS ONE, 2012, 7, e39424.	2.5	52
182	Comparison of 3â€²-deoxy-3â€²-[18F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 846-851.	6.4	51
183	Energy metabolism and proliferation in pancreatic carcinogenesis. Langenbeck's Archives of Surgery, 2012, 397, 507-512.	1.9	21
184	Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology, 2012, 55, 287-297.	7.3	147
185	Asymptomatic pancreatic lesions: New insights and clinical implications. World Journal of Gastroenterology, 2012, 18, 4474.	3.3	1
186	Disclosure of Erlotinib as a Multikinase Inhibitor in Pancreatic Ductal Adenocarcinoma. Neoplasia, 2011, 13, 1026-IN24.	5.3	41
187	Reduced Î±-Dystroglycan Expression Correlates with Shortened Patient Survival in Pancreatic Cancer. Journal of Surgical Research, 2011, 171, 120-126.	1.6	15
188	Further characterization of autologous NeoHepatocytes for in vitro toxicity testing. Toxicology in Vitro, 2011, 25, 1203-1208.	2.4	2
189	Pigment Epithelium-Derived Factor Associates With Neuropathy and Fibrosis in Pancreatic Cancer. American Journal of Gastroenterology, 2011, 106, 968-980.	0.4	37
190	Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet, The, 2011, 377, 1514-1522.	13.7	485
191	Autologous Serum Improves Yield and Metabolic Capacity of Monocyte-Derived Hepatocyte-Like Cells: Possible Implication for Cell Transplantation. Cell Transplantation, 2011, 20, 1465-1478.	2.5	18
192	Massive intra-abdominal bleeding caused by nontraumatic rupture of a vein in the colorenal ligament: Report of a case. Surgery Today, 2011, 41, 415-417.	1.5	2
193	Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer. Abdominal Imaging, 2011, 36, 179-184.	2.0	98
194	Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Krasâ€“MAPK signaling. International Journal of Cancer, 2011, 129, 2349-2359.	5.1	88
195	From tissue turnover to the cell of origin for pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 467-472.	17.8	44
196	Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 427-433.	1.7	44
197	Tumor-Specific Targeting of Pancreatic Cancer with Shiga Toxin B-Subunit. Molecular Cancer Therapeutics, 2011, 10, 1918-1928.	4.1	49
198	Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma. British Journal of Cancer, 2011, 105, 288-295.	6.4	23

#	Article	IF	Citations
199	Palliative Interventional and Surgical Therapy for Unresectable Pancreatic Cancer. Cancers, 2011, 3, 652-661.	3.7	10
200	Simultaneous/Incidental Cholecystectomy During Gastric/Esophageal Resection: Systematic Analysis of Risks and Benefits. World Journal of Surgery, 2010, 34, 1008-1014.	1.6	41
201	Molecular mechanism of pancreatic cancerâ€"understanding proliferation, invasion, and metastasis. Langenbeck's Archives of Surgery, 2010, 395, 295-308.	1.9	64
202	The impact factor rankingâ€"a challenge for scientists and publishers. Langenbeck's Archives of Surgery, 2010, 395, 69-73.	1.9	23
203	Beger's operation and the Berne modification: origin and current results. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 735-744.	2.6	8
204	Multidisciplinary Treatment of Aggressive and Rapidly Progressing Biliary Papillomatosis. Digestive Diseases and Sciences, 2010, 55, 3627-3629.	2.3	2
205	ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer. Journal of Surgical Oncology, 2010, 101, 564-569.	1.7	39
206	T-tube or no T-tube in reconstruction of the biliary tract during orthotopic liver transplantation - systematic review and meta-analysis. Liver Transplantation, 2010, 16, NA-NA.	2.4	45
207	Cystic colon duplication causing intussusception in a 25-year-old man: report of a case and review of the literature. BMC Surgery, 2010, 10, 19.	1.3	26
208	AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-Î²-mediated ERK signaling. Oncogene, 2010, 29, 5146-5158.	5.9	78
209	Expression and Significance of FXYD-3 Protein in Gastric Adenocarcinoma. Disease Markers, 2010, 28, 63-69.	1.3	14
210	Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages. PLoS Medicine, 2010, 7, e1000267.	8.4	1,300
211	Autoantibodies Against the Exocrine Pancreas in Autoimmune Pancreatitis: Gene and Protein Expression Profiling and Immunoassays Identify Pancreatic Enzymes as a Major Target of the Inflammatory Process. American Journal of Gastroenterology, 2010, 105, 2060-2071.	0.4	126
212	B7-H3 and Its Role in Antitumor Immunity. Clinical and Developmental Immunology, 2010, 2010, 1-7.	3.3	101
213	Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines. Cancer Biology and Therapy, 2010, 10, 54-64.	3.4	34
214	Tumor metabolism to blood flow ratio in pancreatic cancer: helpful in patient stratification?. Future Oncology, 2010, 6, 13-15.	2.4	5
215	Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. Molecular Cancer, 2010, 9, 88.	19.2	90
216	Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Biochemical and Biophysical Research Communications, 2010, 401, 422-428.	2.1	30

#	Article	IF	Citations
217	Tumor-Stromal Interactions in Invasion and Metastases. , 2010, , 535-563.		2
218	Reduced expression of the membrane skeleton protein beta1-spectrin (SPTBN1) is associated with worsened prognosis in pancreatic cancer. Histology and Histopathology, 2010, 25, 1497-506.	0.7	22
219	Expression and significance of FXYD-3 protein in gastric adenocarcinoma. Disease Markers, 2010, 28, 63-9.	1.3	13
220	Natural orifice transluminal endoscopic surgery in pancreatic diseases. World Journal of Gastroenterology, 2010, 16, 3859.	3.3	10
221	Expression Pattern and Functional Relevance of Epidermal Growth Factor Receptor and Cyclooxygenase-2: Novel Chemotherapeutic Targets in Pancreatic Endocrine Tumors?. American Journal of Gastroenterology, 2009, 104, 171-181.	0.4	39
222	Expression of FXYD3 Protein in Relation to Biological and Clinicopathological Variables in Colorectal Cancers. Chemotherapy, 2009, 55, 407-413.	1.6	25
223	Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus. Cancer Biology and Therapy, 2009, 8, 1527-1533.	3.4	34
224	Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Molecular Cancer Therapeutics, 2009, 8, 1494-1504.	4.1	91
225	Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer, 2009, 9, 463.	2.6	127
226	MOESIN DEPENDENT CYTOSKELETON REMODELING IS ASSOCIATED WITH AN ANAPLASTIC PHENOTYPE OF PANCREATIC CANCER. Journal of Cellular and Molecular Medicine, 2009, 14, 1166-79.	3.6	29
227	Systematic review and meta-analysis of prophylactic gastroenterostomy for unresectable advanced pancreatic cancer. British Journal of Surgery, 2009, 96, 711-719.	0.3	53
228	Resection of the intrapancreatic bile duct preserving the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery, 2009, 16, 31-34.	2.0	11
229	Molecular biology, models, and histopathology of chronic pancreatitis and pancreatic cancer. European Surgery - Acta Chirurgica Austriaca, 2009, 41, 250-267.	0.7	3
230	Interleukin-13 exerts autocrine growth-promoting effects on human pancreatic cancer, and its expression correlates with a propensity for lymph node metastases. International Journal of Colorectal Disease, 2009, 24, 57-67.	2.2	34
231	Expression of FXYD-3 is an Independent Prognostic Factor in Rectal Cancer Patients With Preoperative Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 137-142.	0.8	21
232	Northern blot analysis for detection and quantification of RNA in pancreatic cancer cells and tissues. Nature Protocols, 2009, 4, 37-43.	12.0	141
233	An audit of outcomes of a series of periampullary carcinomas. European Journal of Surgical Oncology, 2009, 35, 187-191.	1.0	70
234	Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. Cancer Letters, 2009, 277, 72-81.	7.2	42

#	Article	IF	Citations
235	Confirmation of DNA Microarray-Derived Differentially Expressed Genes in Pancreatic Cancer Using Quantitative RT-PCR. Pancreatology, 2009, 9, 577-582.	1.1	16
236	The microtubule-associated protein MAPRE2 is involved in perineural invasion of pancreatic cancer cells. International Journal of Oncology, 2009, 35, 1111-6.	3.3	25
237	Identification of Malignancy Factors by Analyzing Cystic Tumors of the Pancreas. Pancreatology, 2009, 9, 34-44.	1.1	19
238	Cancer-Stellate Cell Interactions Perpetuate the Hypoxia-Fibrosis Cycle in Pancreatic Ductal Adenocarcinoma. Neoplasia, 2009, 11, 497-508.	5.3	253
239	Pancreatic Islet and Stellate Cells Are the Main Sources of Endocrine Gland-Derived Vascular Endothelial Growth Factor/Prokineticin-1 in Pancreatic Cancer. Pancreatology, 2009, 9, 165-172.	1.1	35
240	Defining New Pancreatic Tumour Entities by Molecular Analysis. Pancreatology, 2009, 9, 334-339.	1.1	3
241	Silencing of GRP94 expression promotes apoptosis in pancreatic cancer cells. International Journal of Oncology, 2009, 35, 823-8.	3.3	16
242	Tumor initiating cells in pancreatic cancer: A critical view. World Journal of Stem Cells, 2009, 1, 8.	2.8	11
243	Palliative cardia resection with gastroesophageal reconstruction for perforated carcinoma of the gastroesophageal junction. World Journal of Gastroenterology, 2009, 15, 3065.	3.3	0
244	HED. , 2009, , 787-787.		0
245	Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology, 2008, 47, 511-520.	7.3	173
246	Approaches to localized pancreatic cancer. Current Oncology Reports, 2008, 10, 212-219.	4.0	6
247	Cannabinoids in pancreatic cancer: Correlation with survival and pain. International Journal of Cancer, 2008, 122, 742-750.	5.1	121
248	Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. British Journal of Surgery, 2008, 95, 627-635.	0.3	237
249	Surgical approaches to chronic pancreatitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 167-181.	2.4	22
250	Second-Look Operation for Unresectable Pancreatic Ductal Adenocarcinoma at a High-Volume Center. Annals of Surgical Oncology, 2008, 15, 186-192.	1.5	27
251	Most Pancreatic Cancer Resections are R1 Resections. Annals of Surgical Oncology, 2008, 15, 1651-1660.	1.5	574
252	Surgical Treatment of Pancreatic Cancer. Annals of the New York Academy of Sciences, 2008, 1138, 169-180.	3.8	105

#	Article	IF	Citations
253	Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. British Journal of Cancer, 2008, 99, 760-767.	6.4	48
254	Persisting elevation of C-reactive protein after pancreatic resections can indicate developing inflammatory complications. Surgery, 2008, 143, 20-28.	1.9	109
255	Metastasis to the Pancreas: Characterization by Morphology and Contrast Enhancement Features on CT and MRI. Pancreatology, 2008, 8, 199-203.	1.1	64
256	The Activated Stroma Index Is a Novel and Independent Prognostic Marker in Pancreatic Ductal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2008, 6, 1155-1161.	4.4	361
257	Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. American Journal of Surgery, 2008, 195, 221-228.	1.8	91
258	Is there an advantage in performing a pancreas-preserving total duodenectomy in duodenal adenomatosis?. American Journal of Surgery, 2008, 195, 741-748.	1.8	38
259	Perioperative and follow-up results after central pancreatic head resection (Berne technique) in a consecutive series of patients with chronic pancreatitis. American Journal of Surgery, 2008, 196, 364-372.	1.8	46
260	Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Letters, 2008, 268, 98-109.	7.2	126
261	T1 Pancreatic Cancer With Lymph Node Metastasis and Perineural Invasion of the Celiac Trunk. Clinical Gastroenterology and Hepatology, 2008, 6, e41-e42.	4.4	12
262	Systematic Review and Meta-Analysis of the Role of Defunctioning Stoma in Low Rectal Cancer Surgery. Annals of Surgery, 2008, 248, 52-60.	4.2	512
263	Resection of Primary Pancreatic Cancer and Liver Metastasis: A Systematic Review. Digestive Surgery, 2008, 25, 473-480.	1.2	87
264	Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biology and Therapy, 2008, 7, 1352-1359.	3.4	98
265	AMPA RECEPTOR ANTAGONISM INHIBITS PANCREATIC CANCER GROWTH. Pancreas, 2008, 37, 485.	1.1	1
266	In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors. Journal of Nuclear Medicine, 2008, 49, 1437-1444.	5.0	42
267	Proliferation of Colo-357 Pancreatic Carcinoma Cells and Survival of Patients With Pancreatic Carcinoma Are Not Altered by Insulin Glargine. Diabetes Care, 2008, 31, 1105-1111.	8.6	28
268	Nonmetastatic Pancreatic Cancer: Many Trials, Little Progress. Journal of Clinical Oncology, 2008, 26, 3100-3100.	1.6	6
269	Management postoperativer und postinterventioneller Gallenwegskomplikationen. Chirurgische Gastroenterologie Interdisziplinar, 2008, 24, 115-123.	0.0	0
270	CANCER-STELLATE CELL INTERACTIONS INHIBIT ANGIOGENESIS AND PERPETUATE THE HYPOXIA-FIBROSIS CYCLE IN PANCREATIC CANCER. Pancreas, 2008, 37, 469.	1.1	0

#	Article	IF	Citations
271	Re: Distal Pancreatectomy. Annals of Surgery, 2008, 247, 393.	4.2	1
272	Autoimmune Pancreatocholangitis, Non-Autoimmune Pancreatitis and Primary Sclerosing Cholangitis: A Comparative Morphological and Immunological Analysis. PLoS ONE, 2008, 3, e2539.	2.5	35
273	Cannabinoids Reduce Markers of Inflammation and Fibrosis in Pancreatic Stellate Cells. PLoS ONE, 2008, 3, e1701.	2.5	47
274	Loss of ONECUT1 expression in human pancreatic cancer cells. Oncology Reports, 2008, 19, 157-63.	2.6	12
275	Expression of the Shwachman-Bodian-Diamond syndrome (SBDS) protein in human pancreatic cancer and chronic pancreatitis. Histology and Histopathology, 2008, 23, 819-26.	0.7	2
276	Molecular Pathogenesis of Pancreatic Cancer: Advances and Challenges. Current Molecular Medicine, 2007, 7, 504-521.	1.3	61
277	Expression of extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) in pancreatic neoplasm and pancreatic stellate cells. Cancer Biology and Therapy, 2007, 6, 218-227.	3.4	52
278	Basic transcription factor 3 (BTF3) regulates transcription of tumor-associated genes in pancreatic cancer cells. Cancer Biology and Therapy, 2007, 6, 367-376.	3.4	63
279	INTERLEUKIN-13 EXERTS AUTOCRINE GROWTH PROMOTING EFFECTS IN HUMAN PANCREATIC CANCER AND ITS EXPRESSION CORRELATES WITH A PROPENSITY FOR LYMPH NODE METASTASES. Pancreas, 2007, 35, 402.	1.1	0
280	Suppression of transforming growth factor Â signalling aborts caerulein induced pancreatitis and eliminates restricted stimulation at high caerulein concentrations. Gut, 2007, 56, 685-692.	12.1	77
281	Preoperative Acute Pancreatitis in Periampullary Tumors: Implications for Surgical Management. Digestion, 2007, 75, 165-171.	2.3	11
282	Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12890-12895.	7.1	198
283	Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. International Journal of Oncology, 2007, 30, 91.	3.3	25
284	Is There Still a Role for Total Pancreatectomy?. Annals of Surgery, 2007, 246, 966-975.	4.2	240
285	Hypothetical Progression Model of Pancreatic Cancer With Origin in the Centroacinar-Acinar Compartment. Pancreas, 2007, 35, 212-217.	1.1	62
286	Surgery for Recurrent Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2007, 245, 566-572.	4.2	217
287	Distal Pancreatectomy. Annals of Surgery, 2007, 245, 573-582.	4.2	358
288	Local pancreatic resection with preoperative endoscopic transpapillary stenting. American Journal of Surgery, 2007, 194, 311-312.	1.8	4

#	Article	IF	Citations
289	Activation of growth factor receptors in pancreatic cancer. American Journal of Surgery, 2007, 194, S76-S83.	1.8	1
290	Surgical treatment of pancreatic cancer: The role of adjuvant and multimodal therapies. European Journal of Surgical Oncology, 2007, 33, 817-823.	1.0	36
291	Effects of bone sialoprotein on pancreatic cancer cell growth, invasion and metastasis. Cancer Letters, 2007, 245, 171-183.	7.2	14
292	3513 POSTER Interleukin-13 exerts autocrine growth promoting effects in human pancreatic cancer and its expression correlates with a propensity for lymph node metastases. European Journal of Cancer, Supplement, 2007, 5, 263.	2.2	0
293	Tumor-Suppressor Function of SPARC-Like Protein 1/Hevin in Pancreatic Cancer. Neoplasia, 2007, 9, 8-17.	5.3	74
294	BGLAP is expressed in pancreatic cancer cells and increases their growth and invasion. Molecular Cancer, 2007, 6, 83.	19.2	19
295	Mononuclear cells modulate the activity of pancreatic stellate cells which in turn promote fibrosis and inflammation in chronic pancreatitis. Journal of Translational Medicine, 2007, 5, 63.	4.4	35
296	Periostin Creates a Tumor-Supportive Microenvironment in the Pancreas by Sustaining Fibrogenic Stellate Cell Activity. Gastroenterology, 2007, 132, 1447-1464.	1.3	273
297	Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. British Journal of Surgery, 2007, 94, 265-273.	0.3	284
298	Neoadjuvant therapy for pancreatic cancer. British Journal of Surgery, 2007, 94, 261-262.	0.3	35
299	Expression and differential signaling of heregulins in pancreatic cancer cells. International Journal of Cancer, 2007, 120, 514-523.	5.1	34
300	Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. International Journal of Cancer, 2007, 121, 21-32.	5.1	85
301	Pancreatic cancer microenvironment. International Journal of Cancer, 2007, 121, 699-705.	5.1	190
302	Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. British Journal of Cancer, 2007, 97, 1106-1115.	6.4	62
303	Hepatobiliary and pancreatic: Autoimmune pancreatitis. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 592-592.	2.8	0
304	Surgical Treatment of Pancreatic Cancer. Journal of the American College of Surgeons, 2007, 205, S81-S86.	0.5	37
305	ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. Journal of Cellular and Molecular Medicine, 2007, 11, 1162-1174.	3.6	79
306	Pancreatic cancer â€" Curative resection. Chinese-German Journal of Clinical Oncology, 2007, 6, 149-153.	0.1	0

#	Article	IF	Citations
307	Pancreatic cancer â€" Surgery for recurrent disease. Chinese-German Journal of Clinical Oncology, 2007, 6, 159-161.	0.1	0
308	Dissection of the uncinate process and pancreatic head behind the portal vein using endovascular staplers. Journal of Hepato-Biliary-Pancreatic Surgery, 2007, 14, 480-483.	2.0	8
309	Solid type clear cell carcinoma of the pancreas: differential diagnosis of an unusual case and review of the literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 719-726.	2.8	6
310	Pancreatic anastomosis after pancreaticoduodenectomy: how we do it. Indian Journal of Surgery, 2007, 69, 224-229.	0.3	21
311	Fast Trackâ€"Different Implications in Pancreatic Surgery. Journal of Gastrointestinal Surgery, 2007, 11, 880-887.	1.7	116
312	Die Entwicklung des â€žEuropÃischen Pankreaszentrums Heidelbergâ€œ (EPZ). , 2007, , 109-126.		0
313	Current status on molecular markers and targets in pancreatic disease. European Journal of Cancer, Supplement, 2006, 4, 11.	2.2	0
314	P10. Effects of bone sialoprotein on pancreatic cancer cell growth, invasion and metastasis. European Journal of Cancer, Supplement, 2006, 4, 30-31.	2.2	0
315	Mitogen-Activated Protein Kinases and Chemoresistance in Pancreatic Cancer Cells. Journal of Surgical Research, 2006, 136, 325-335.	1.6	70
316	Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma. International Journal of Molecular Medicine, 2006, 17, 761.	4.0	8
317	Correlation of glypican-1 expression with TGF-Î², BMP, and activin receptors in pancreatic ductal adenocarcinoma. International Journal of Oncology, 2006, 29, 1139.	3.3	18
318	Chronische Pankreatitis und Schmerz â€" chirurgische Sicht. Visceral Medicine, 2006, 22, 21-26.	1.3	0
319	Pancreatic Cancer. Pancreas, 2006, 33, 111-118.	1.1	115
320	ADRENOMEDULLIN (ADM) IS INDUCED BY HYPOXIA AND ENHANCES PANCREATIC CANCER CELL INVASION. Pancreas, 2006, 33, 474-475.	1.1	0
321	Middle Segmental Pancreatic Resection. Annals of Surgery, 2006, 244, 909-920.	4.2	132
322	Hedgehog Signaling in the Normal and Diseased Pancreas. Pancreas, 2006, 32, 119-129.	1.1	60
323	Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. Journal of Pathology, 2006, 208, 673-685.	4.5	142
324	Update on pancreatic cancer and alcohol-associated risk. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, S69-S75.	2.8	31

#	Article	IF	Citations
325	GUEST EDITORIAL. Hpb, 2006, 8, 323.	0.3	0
326	Pancreatic Resection for M1 Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2006, 14, 118-127.	1.5	201
327	Management of Pain in Small Duct Chronic Pancreatitis. Journal of Gastrointestinal Surgery, 2006, 10, 227-233.	1.7	28
328	Expression of cytokeratin-20 in pancreatic cancer: An indicator of poor outcome after R0 resection. Surgery, 2006, 139, 104-108.	1.9	10
329	A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer, 2006, 6, 285.	2.6	103
330	FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. International Journal of Cancer, 2006, 118, 43-54.	5.1	59
331	Expression of MAC30 in Rectal Cancers with or without Preoperative Radiotherapy. Oncology, 2006, 71, 259-265.	1.9	18
332	Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. Journal of Clinical Pathology, 2006, 60, 885-895.	2.0	46
333	Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. Journal of Clinical Pathology, 2006, 59, 580-584.	2.0	41
334	Hsulf-1 regulates growth and invasion of pancreatic cancer cells. Journal of Clinical Pathology, 2006, 59, 1052-1058.	2.0	33
335	Aberrant Gata-3 Expression in Human Pancreatic Cancer. Journal of Histochemistry and Cytochemistry, 2006, 54, 161-169.	2.5	37
336	Management of Early Hemorrhage from Pancreatic Anastomoses after Pancreaticoduodenectomy. Digestive Surgery, 2006, 23, 203-208.	1.2	38
337	What is the best strategy for the surgical management of patients with necrotizing pancreatitis?. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 616-617.	1.7	0
338	Autoimmune pancreatitis associated with a large pancreatic pseudocyst. World Journal of Gastroenterology, 2006, 12, 5904.	3.3	33
339	Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma. International Journal of Molecular Medicine, 2006, 17, 761-7.	4.0	22
340	Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. Anticancer Research, 2006, 26, 3265-73.	1.1	40
341	Osteonectin Influences Growth and Invasion of Pancreatic Cancer Cells. Annals of Surgery, 2005, 242, 224-234.	4.2	89
342	Renal Cancer Cell Metastasis Into the Pancreas. Pancreas, 2005, 30, 218-222.	1.1	141

#	Article	IF	Citations
343	Complications of pancreatic surgery. Hpb, 2005, 7, 99-108.	0.3	179
344	Effect of Antecolic Reconstruction on Delayed Gastric Emptying After the Pylorus-Preserving Whipple Procedure. Archives of Surgery, 2005, 140, 1094.	2.2	131
345	Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene, 2005, 24, 4421-4432.	5.9	187
346	Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine. Laboratory Investigation, 2005, 85, 1276-1291.	3.7	137
347	Localization of the human hedgehogâ€interacting protein (Hip) in the normal and diseased pancreas. Molecular Carcinogenesis, 2005, 42, 183-192.	2.7	32
348	DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors. Investigational New Drugs, 2005, 23, 339-347.	2.6	17
349	The presence of the proteolysis-inducing factor in urine does not predict the malignancy of a pancreatic tumour. BMC Gastroenterology, 2005, 5, 20.	2.0	9
350	Melanoma Inhibitory Activity (MIA) increases the invasiveness of pancreatic cancer cells. Cancer Cell International, 2005, 5, 3.	4.1	24
351	Expression Analysis of PMP22/Gas3 in Premalignant and Malignant Pancreatic Lesions. Journal of Histochemistry and Cytochemistry, 2005, 53, 885-893.	2.5	18
352	Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biology and Therapy, 2005, 4, 740-746.	3.4	84
353	Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Molecular Cancer, 2005, 4, 14.	19.2	81
354	Pancreatic metastasis of Merkel cell carcinoma and concomitant insulinoma: case report and literature review. World Journal of Surgical Oncology, 2005, 3, 58.	1.9	23
355	KAI1 inhibits anchorage-dependent and -independent pancreatic cancer cell growth. Oncology Reports, 2005, 14, 59-63.	2.6	11
356	RUNX3 expression in primary and metastatic pancreatic cancer. Journal of Clinical Pathology, 2004, 57, 294-299.	2.0	47
357	Moxifloxacin penetration into human gastrointestinal tissues. Journal of Antimicrobial Chemotherapy, 2004, 53, 875-877.	3.0	38
358	Gefitinib (â€˜Iressaâ€™, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. International Journal of Oncology, 2004, 25, 203.	3.3	25
359	DISTINCT EXPRESSION OF CXC CHEMOKINES IN HUMAN PANCREATIC CANCER TISSUES.. Pancreas, 2004, 29, 358.	1.1	0
360	What is the most accurate test to differentiate pancreatic cystic neoplasms?. Nature Reviews Gastroenterology & Hepatology, 2004, 1, 18-19.	1.7	2

#	Article	IF	Citations
361	Thioredoxin Is Downstream of Smad7 in a Pathway That Promotes Growth and Suppresses Cisplatin-Induced Apoptosis in Pancreatic Cancer. Cancer Research, 2004, 64, 3599-3606.	0.9	60
362	Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis, 2004, 25, 1575-1585.	2.8	65
363	Loss of heterozygosity in the HLA class I region in human pancreatic cancer. Tissue Antigens, 2004, 64, 696-702.	1.0	30
364	Cartilage oligomeric matrix protein expression in hepatocellular carcinoma and the cirrhotic liver. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 296-302.	2.8	21
365	Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene, 2004, 23, 71-81.	5.9	68
366	Still any role for transduodenal local excision in tumors of the papilla of Vater?. Journal of Hepato-Biliary-Pancreatic Surgery, 2004, 11, 239-44.	2.0	34
367	Microcystic tubulopapillary carcinoma of the pancreas: a new tumor entity?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 447-453.	2.8	34
368	Indian hedgehog signaling pathway: Expression and regulation in pancreatic cancer. International Journal of Cancer, 2004, 110, 668-676.	5.1	91
369	Glypican-1 antisense transfection modulates TGF-Î²-dependent signaling in Colo-357 pancreatic cancer cells. Biochemical and Biophysical Research Communications, 2004, 320, 1148-1155.	2.1	55
370	LOCALIZATION OF THE HUMAN HEDGEHOG-INTERACTING PROTEIN (HIP) IN THE NORMAL AND DISEASED PANCREAS.. Pancreas, 2004, 29, 327.	1.1	0
371	Adenovirus-Mediated Transfer of a Truncated Fibroblast Growth Factor (FGF) Type I Receptor Blocks FGF-2 Signaling in Multiple Pancreatic Cancer Cell Lines. Pancreas, 2004, 28, 25-30.	1.1	15
372	Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. International Journal of Oncology, 2004, 25, 203-10.	3.3	30
373	Detection of oncogenes in chronic pancreatitis. Hpb, 2003, 5, 214-225.	0.3	3
374	â€œHow I Do Itâ€•session: pancreatitisâ€”molecular biology update. Journal of Gastrointestinal Surgery, 2003, 7, 939.	1.7	0
375	Molecular pathophysiology of chronic pancreatitisâ€”an update. Journal of Gastrointestinal Surgery, 2003, 7, 943-945.	1.7	14
376	Heparanase expression in hepatocellular carcinoma and the cirrhotic liver. Hepatology Research, 2003, 26, 192-198.	3.4	34
377	Pancreatic fistula after pancreatic head resection: A problem of the past?. Gastroenterology, 2003, 124, A822.	1.3	0
378	Disturbance of the substance P/neurokinin receptor 1 pathway in inflammatory bowel disease. Gastroenterology, 2003, 124, A334.	1.3	0

#	Article	IF	Citations
379	Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology, 2003, 124, 1830-1845.	1.3	92
380	Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue. Gastroenterology, 2003, 125, 98-106.	1.3	66
381	Adenovirus mediated transfer of a truncated fibroblast growth factor (FGF) typ I receptor blocks FGF2 signaling in pancreatic cancer cells. Gastroenterology, 2003, 124, A104.	1.3	1
382	Effects of STI571 (gleevec) on pancreatic cancer cell growth. Molecular Cancer, 2003, 2, 32.	19.2	42
383	Central pancreatic head resection in chronic pancreatitis È•a new simple surgical approach to solve head related complications: First results of a phase I prospective evaluation. Gastroenterology, 2003, 124, A821.	1.3	0
384	How Helicobacter pylori Changed the Life of Surgeons. Digestive Surgery, 2003, 20, 93-102.	1.2	13
385	Distribution of Indian hedgehog and its receptors patched and smoothened in human chronic pancreatitis. Journal of Endocrinology, 2003, 178, 467-478.	2.6	52
386	COMP is Selectively Up-regulated in Degenerating Acinar Cells in Chronic Pancreatitis and in Chronic-Pancreatitis-like Lesions in Pancreatic Cancer. Scandinavian Journal of Gastroenterology, 2003, 38, 207-215.	1.5	23
387	Management of Hepatobiliary Cystadenocarcinoma. Digestive Surgery, 2003, 20, 60-63.	1.2	11
388	Gene-expression analysis of single cells-nested polymerase chain reaction after laser microdissection. World Journal of Gastroenterology, 2003, 9, 1337.	3.3	7
389	Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Research, 2003, 23, 251-8.	1.1	17
390	Detection of circulating tumor cells by cytokeratin 20 and prostate stem cell antigen RT-PCR in blood of patients with gastrointestinal cancers. Anticancer Research, 2003, 23, 2711-6.	1.1	25
391	Acquired Resistance of Pancreatic Cancer Cells towards 5-Fluorouracil and Gemcitabine Is Associated with Altered Expression of Apoptosis-Regulating Genes. Oncology, 2002, 62, 354-362.	1.9	152
392	Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal cancer. American Journal of Surgery, 2002, 184, 78-83.	1.8	25
393	Induction and expression of Î²ig-h3 in pancreatic cancer cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2002, 1588, 1-6.	3.8	53
394	Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Molecular Carcinogenesis, 2002, 35, 138-147.	2.7	92
395	Influences of the lysosomal associated membrane proteins (Lampâ€1, Lampâ€2) and Macâ€2 binding protein (Macâ€2â€BP) on the prognosis of pancreatic carcinoma. Cancer, 2002, 94, 228-239.	4.1	75
396	Molecular alterations in chronic pancreatitis. Journal of Hepato-Biliary-Pancreatic Surgery, 2002, 9, 653-658.	2.0	1

#	Article	IF	Citations
397	Down-Regulation of DOC-2 in Colorectal Cancer Points to Its Role as a Tumor Suppressor in This Malignancy. Diseases of the Colon and Rectum, 2002, 45, 1242-1248.	1.3	45
398	Immunohistochemical presentation in non-malignant and malignant Barrettâ€™s epithelium*. Ecological Management and Restoration, 2002, 15, 10-15.	0.4	9
399	Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors. Cancer Gene Therapy, 2002, 9, 522-532.	4.6	28
400	Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene, 2002, 21, 6059-6070.	5.9	123
401	The Stem Cell Factorâ€“c-kit System and Mast Cells in Human Pancreatic Cancer. Laboratory Investigation, 2002, 82, 1481-1492.	3.7	77
402	Bile duct infarction following intraarterial hepatic chemotherapy mimicking multiple liver metastasis: report of a case and review of the literature. Digestive Diseases and Sciences, 2002, 47, 338-344.	2.3	6
403	Surgical approaches for resection of pancreatic cancer: an overview. Hepatobiliary and Pancreatic Diseases International, 2002, 1, 118-25.	1.3	6
404	The human endo-glycosidase heparanase is over-expressed in primary and metastatic pancreatic cancer. Gastroenterology, 2001, 120, A160.	1.3	0
405	Co-Existent Chronic Pancreatitis and Pancreatic Neuroendocrine Tumor. Pancreatology, 2001, 1, 117-122.	1.1	8
406	Mast cell distribution and activation in chronic pancreatitis. Human Pathology, 2001, 32, 1174-1183.	2.0	72
407	Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Letters, 2001, 163, 71-81.	7.2	79
408	The anti-apoptotic protein BAG-3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines. FEBS Letters, 2001, 503, 151-157.	2.8	133
409	Differential localization and activation of mast cells in chronic pancreatitis of different etiologies. Gastroenterology, 2001, 120, A645.	1.3	1
410	Pancreatic Cancer: Factors Regulating Tumor Development, Maintenance and Metastasis. Pancreatology, 2001, 1, 517-524.	1.1	42
411	Timing and Extent of Surgical Intervention in Patients from Hereditary Pancreatic Cancer Kindreds. Pancreatology, 2001, 1, 525-530.	1.1	12
412	Identification of Disease-specific Genes in Chronic Pancreatitis Using DNA Array Technology. Annals of Surgery, 2001, 234, 769-779.	4.2	55
413	Altered Expression and Localization of the Tight Junction Protein ZO-1 in Primary and Metastatic Pancreatic Cancer. Pancreas, 2001, 23, 259-265.	1.1	53
414	A Chair Leg as the Rare Cause of a Transabdominal Impalement with Duodenal and Pancreatic Involvement. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 51, 164-167.	2.4	12

#	Article	IF	Citations
415	Bcl-xl antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. International Journal of Cancer, 2001, 94, 268-274.	5.1	60
416	Growth factors and their receptors in pancreatic cancer. Teratogenesis, Carcinogenesis, and Mutagenesis, 2001, 21, 27-44.	0.8	76
417	DOC-2/hDab2 Expression Is Up-Regulated in Primary Pancreatic Cancer but Reduced in Metastasis. Laboratory Investigation, 2001, 81, 863-873.	3.7	26
418	Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 2001, 48, 558-564.	12.1	248
419	Overexpression of activin A in stage IV colorectal cancer. Gut, 2001, 49, 409-417.	12.1	87
420	Cyclooxygenase 2 Expression in Chronic Pancreatitis: Correlation with Stage of the Disease and Diabetes mellitus. Digestion, 2001, 64, 240-247.	2.3	31
421	The human endo-glycosidase heparanase is over-expressed in primary and metastatic pancreatic cancer. Gastroenterology, 2001, 120, A160-A160.	1.3	0
422	Differential localization and activation of mast cells in chronic pancreatitis of different etiologies. Gastroenterology, 2001, 120, A645-A645.	1.3	0
423	Expression of the Multidrug-Resistance 1 (MDR1) Gene and Prognosis in Human Pancreatic Cancer. Pancreas, 2000, 21, 240-247.	1.1	44
424	Fas and Fas-Ligand Expression in Human Pancreatic Cancer. Annals of Surgery, 2000, 231, 368-379.	4.2	46
425	Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. International Journal of Cancer, 2000, 86, 399-407.	5.1	109
426	Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. International Journal of Cancer, 2000, 88, 12-20.	5.1	130
427	Fluconazole Penetration into the Pancreas. Antimicrobial Agents and Chemotherapy, 2000, 44, 2569-2571.	3.2	36
428	Enhanced Expression of Silencer of Death Domains (SODD/BAG-4) in Pancreatic Cancer. Biochemical and Biophysical Research Communications, 2000, 271, 409-413.	2.1	49
429	Epiregulin Is Up-Regulated in Pancreatic Cancer and Stimulates Pancreatic Cancer Cell Growth. Biochemical and Biophysical Research Communications, 2000, 273, 1019-1024.	2.1	82
430	Glypican-3 is a potential tumor marker for hepatocellular carcinoma. Gastroenterology, 2000, 118, A261.	1.3	0
431	Increased sensitivity to gemcitabine following Bcl-xL antisense treatment in pancreatic cancer cells. Gastroenterology, 2000, 118, A521.	1.3	0
432	Reduction of the angiostatic chemokine SF-1 and concomitant increase of its receptor CXCR-4 in colorectal cancer. Gastroenterology, 2000, 118, A769.	1.3	0

#	Article	IF	Citations
433	Connective tissue growth factor as an inducer of fibrosis in human liver cirrhosis. Gastroenterology, 2000, 118, A452.	1.3	0
434	Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. , 2000, 86, 399.		1
435	Pancreatic Cancer - New Aspects of Molecular Biology Research. Swiss Surgery = Schweizer Chirurgie = Chirurgie Suisse = Chirurgia Svizzera, 2000, 6, 231-234.	0.3	21
436	Molecular Aspects of Pancreatic Cancer and Future Perspectives. Digestive Surgery, 1999, 16, 281-290.	1.2	77
437	The TGF-Î² signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene, 1999, 18, 5363-5372.	5.9	248
438	Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer. Digestive Diseases and Sciences, 1999, 44, 1793-1802.	2.3	29
439	Detection and localization of MIP-3?/LARC/exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. , 1999, 81, 650-657.		139
440	The impact of different types of surgery in pancreatic cancer. European Journal of Surgical Oncology, 1999, 25, 124-131.	1.0	27
441	Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology, 1999, 116, 1202-1216.	1.3	160
442	Id-1 and Id-2 Are Overexpressed in Pancreatic Cancer and in Dysplastic Lesions in Chronic Pancreatitis. American Journal of Pathology, 1999, 155, 815-822.	3.8	137
443	Smad6 Suppresses TGF-Î²-Induced Growth Inhibition in COLO-357 Pancreatic Cancer Cells and Is Overexpressed in Pancreatic Cancer. Biochemical and Biophysical Research Communications, 1999, 255, 268-273.	2.1	102
444	Gentherapie bei gastrointestinalen Tumoren am Beispiel des Pankreaskarzinoms: Standortbestimmung und Perspektiven. Visceral Medicine, 1999, 15, 181-187.	1.3	0
445	Molekulare VerÃnderungen bei Pankreas- und periampullÃren Karzinomen. Visceral Medicine, 1999, 15, 150-157.	1.3	4
446	Stable Transfection of a Glypican-1 Antisense Construct Decreases Tumorigenicity in PANC-1 Pancreatic Carcinoma Cells. Pancreas, 1999, 19, 281-288.	1.1	57
447	Ligand Induced Upregulation of the Type II Transforming Growth Factor (TGF-Î²) Receptor Enhances TGF-P Responsiveness in COLO-357 Cells. Pancreas, 1999, 18, 364-370.	1.1	17
448	Enhanced Expression of the Type II Transforming Growth Factor-Î² Receptor Is Associated with Decreased Survival in Human Pancreatic Cancer. Pancreas, 1999, 19, 370-376.	1.1	76
449	Prevention and Treatment of Complications in Pancreatic Cancer Surgery. Digestive Surgery, 1999, 16, 327-336.	1.2	58
450	Characterization of cytokeratin 20 expression in pancreatic and colorectal cancer. Clinical Cancer Research, 1999, 5, 2840-7.	7.0	45

#	Article	IF	Citations
451	Influence of High-Dose Pancreatic Enzyme Treatment on Pancreatic Function in Healthy Volunteers. International Journal of Gastrointestinal Cancer, 1998, 23, 115-124.	0.4	10
452	The Role of Diagnostic Laparoscopy in Pancreatic and Periampullary Malignancies. Journal of the American College of Surgeons, 1998, 186, 675-682.	0.5	133
453	Concomitant over-expression of activin/inhibin Î² subunits and their receptors in human pancreatic cancer. , 1998, 77, 860-868.		53
454	Transfection of the type I TGF-Î² receptor restores TGF-Î² responsiveness in pancreatic cancer. , 1998, 78, 255-260.		63
455	The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings. Surgery, 1998, 124, 79-86.	1.9	14
456	Adaptation of the human pancreas to inhibition of luminal proteolytic activity. Gastroenterology, 1998, 115, 388-396.	1.3	24
457	Transcriptional up-regulation of transforming growth factor-Î² (TGF-Î²) receptors by TGF-Î²1 correlates with expression of cyclin d-dependent kinase inhibitors. Gastroenterology, 1998, 114, A626.	1.3	0
458	Up-regulation of Transforming Growth Factor (TGF)-Î² Receptors by TGF-Î²1 in COLO-357 Cells. Journal of Biological Chemistry, 1998, 273, 7495-7500.	3.4	68
459	The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer.. Journal of Clinical Investigation, 1998, 102, 1662-1673.	8.2	316
460	Gastric emptying following pylorus-preserving whipple and duodenum-preserving pancreatic head resection in patients with chronic pancreatitis. American Journal of Surgery, 1997, 173, 257-263.	1.8	108
461	Molecular versus Conventional Markers in Pancreatic Cancer. Digestion, 1997, 58, 557-563.	2.3	15
462	Clinical Applicability of Molecular Procedures in the Diagnosis of Pancreatic Cancer. , 1997, , 411-423.		0
463	Loss of ONECUT1 expression in human pancreatic cancer cells. Oncology Reports, 0, , .	2.6	9
464	Preoperative chemoradiotherapy versus chemotherapy for adenocarcinoma of the esophagus and esophagogastric junction (AEG): systematic review with individual participant data (IPD) network meta-analysis (NMA). The Cochrane Library, 0, , .	2.8	1
465	Pancreatic carcinoma: surgery, palliative resection and value of lymph node resection. , 0, , 114-119.		0
466	Role of Positron Emission Tomography in Diagnosis of Pancreatic Cancer and Cancer Recurrence. , 0, , 648-657.		3
467	Palliative Pancreaticoduodenectomy: Benefits and Limitations. , 0, , 714-718.		0
468	Management of Cancer Recurrence. , 0, , 772-775.		0